Inflarx NV (NASDAQ:IFRX) was the recipient of a large increase in short interest in the month of June. As of June 30th, there was short interest totalling 1,242,600 shares, an increase of 32.0% from the May 30th total of 941,700 shares. Approximately 8.2% of the shares of the stock are short sold. Based on an average daily volume of 1,560,000 shares, the short-interest ratio is presently 0.8 days.
Several research analysts have commented on IFRX shares. ValuEngine downgraded shares of Zosano Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Raymond James reissued a “buy” rating on shares of Precision Drilling in a report on Wednesday, June 5th. Leerink Swann downgraded shares of Inflarx from an “outperform” rating to a “market perform” rating in a report on Wednesday, June 5th. Guggenheim downgraded shares of Inflarx from a “buy” rating to a “neutral” rating and cut their price target for the company from $65.00 to $6.00 in a report on Wednesday, June 5th. Finally, SunTrust Banks downgraded shares of Inflarx from a “buy” rating to a “hold” rating and cut their price target for the company from $55.00 to $5.00 in a report on Wednesday, June 5th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $15.72.
NASDAQ:IFRX traded down $0.04 during trading hours on Friday, hitting $3.24. The stock had a trading volume of 733,035 shares, compared to its average volume of 1,270,417. The business’s 50 day moving average price is $11.08. Inflarx has a one year low of $2.91 and a one year high of $53.10. The stock has a market cap of $85.16 million, a price-to-earnings ratio of -2.31 and a beta of -1.52.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Redmile Group LLC lifted its holdings in shares of Inflarx by 7.2% during the 1st quarter. Redmile Group LLC now owns 2,182,638 shares of the company’s stock worth $82,482,000 after acquiring an additional 147,238 shares during the last quarter. RA Capital Management LLC lifted its holdings in shares of Inflarx by 6.0% during the 4th quarter. RA Capital Management LLC now owns 2,085,089 shares of the company’s stock worth $75,835,000 after acquiring an additional 117,241 shares during the last quarter. FMR LLC bought a new stake in shares of Inflarx during the 1st quarter worth $9,609,000. Polar Capital LLP lifted its holdings in shares of Inflarx by 54.4% during the 4th quarter. Polar Capital LLP now owns 141,887 shares of the company’s stock worth $5,160,000 after acquiring an additional 50,000 shares during the last quarter. Finally, Victory Capital Management Inc. bought a new stake in shares of Inflarx during the 1st quarter worth $3,094,000. 55.89% of the stock is owned by institutional investors.
Inflarx Company Profile
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.
Further Reading: The primary rules of Elliott Wave theory
Receive News & Ratings for Inflarx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx and related companies with MarketBeat.com's FREE daily email newsletter.